RSS-Feed abonnieren

DOI: 10.1055/s-0045-1809352
Clinical and Survival Insights into Carcinoma Penis: A Retrospective Analysis at a Tertiary Care Facility
Authors
Funding None.

Abstract
Objective
The main objective was to evaluate key survival results, comprising progression-free survival (PFS) and overall survival (OS), in individuals with histopathologically confirmed penile cancer, along with an assessment of clinical features, treatment strategies, and therapy-related side effects.
Materials and Methods
This study comprised retrospective analyses of individuals diagnosed with penile cancer, confirmed by histology, between April 2021 and December 2024, regardless of disease stage. Case records were reviewed to gather information on demographics, clinical details, histopathology, and treatment outcomes.
Statistical Analysis
As the data was collected retrospectively, no prior sample size estimate was performed. Data analysis was carried out using SPSS version 27.
Results
The most common presenting symptoms were ulcerative-proliferative growth (60%), pain (50%), dysuria (40%), and lymphedema (40%). The median age of patients in this retrospective study was 56 years (interquartile range: 49.25–59.25). Out of the 10 patients included, 9 (90%) had localized or locally advanced disease and underwent primary surgical treatment. Among them, eight patients (80%) had partial penectomy, while one patient (10%) underwent total penectomy. These patients received adjuvant chemotherapy and/or radiotherapy based on their disease stage. One patient (10%) had metastatic disease at diagnosis and was treated with upfront palliative chemotherapy. Most patients presented with advanced-stage tumors, with 60% having T3/T4 disease and 90% showing lymph node involvement (N + ). For those with nonmetastatic disease, the median disease-free survival was 14 months (95% confidence interval [CI]: 12.61–15.38). Following disease progression, patients were treated with palliative intent, achieving a median PFS of 12 months (95% CI: 11.29–12.71) and a median OS of 28 months (95% CI: 24.9–31.09). Two patients (20%) experienced grade 3 or higher neutropenia, and one patient had hypothyroidism.
Conclusion
In India, penile cancer is frequently identified at an advanced stage. Patients presenting with recurrent, metastatic, or nodal disease tend to have poor OS, even with optimal palliative systemic therapy. This highlights a significant unmet need for more effective systemic treatment options in this group. Our study underscores the pressing need for region-specific research and improved access to multidisciplinary care.
Keywords
clinical profile - survival - carcinoma penis - overall survival - disease-free survival - progression-free survivalAuthors' Contributions
All authors contributed equally and did the critical revision of the final manuscript. All authors read and approved the final manuscript.
Declaration of Generative AI
The authors declare that they have not used any generative artificial intelligence (AI) and AI-assisted technologies in the writing process.
Patient Consent
Informed consent was obtained from all the patients for both participation and publication of the details.
Ethical Approval
This study was approved by the institutional review board and the patient's consent was taken. All procedures performed in our study involving any human participation were in accordance with the ethical standards of the institutional and/or national research committee and in compliance with the 1964 Helsinki Declaration and its later amendments.
Availability of Data and Material
All data generated or analyzed during this study are included in this published article, and referenced articles are listed in the reference section.
Publikationsverlauf
Eingereicht: 11. März 2025
Angenommen: 02. Mai 2025
Artikel online veröffentlicht:
22. Mai 2025
© 2025. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Montes Cardona CE, García-Perdomo HA. Incidence of penile cancer worldwide: systematic review and meta-analysis. Rev Panam Salud Publica 2017; 41: e117
- 2 Mathur P, Sathishkumar K, Chaturvedi M. et al; ICMR-NCDIR-NCRP Investigator Group. Cancer Statistics, 2020: report from National Cancer Registry Programme, India. JCO Glob Oncol 2020; 6 (06) 1063-1075
- 3 Garg V, Ray M, Haresh KP. et al. Clinical profile and predictors of survival in carcinoma penis patients. Curr Oncol 2023; 30 (05) 4563-4574
- 4 Sanchez DF, Soares F, Alvarado-Cabrero I. et al. Pathological factors, behavior, and histological prognostic risk groups in subtypes of penile squamous cell carcinomas (SCC). Semin Diagn Pathol 2015; 32 (03) 222-231
- 5 Dillner J, von Krogh G, Horenblas S, Meijer CJLM. Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl 2000; 34 (205) 189-193
- 6 Yuvaraja TB, Waigankar S, Bakshi G, Prakash G. Genitourinary cancers: summary of Indian data. South Asian J Cancer 2016; 5 (03) 122-124
- 7 Pandey D, Mahajan V, Kannan RR. Prognostic factors in node-positive carcinoma of the penis. J Surg Oncol 2006; 93 (02) 133-138
- 8 Djajadiningrat RS, Bergman AM, van Werkhoven E, Vegt E, Horenblas S. Neoadjuvant taxane-based combination chemotherapy in patients with advanced penile cancer. Clin Genitourin Cancer 2015; 13 (01) 44-49
- 9 Sharma P, Djajadiningrat R, Zargar-Shoshtari K. et al. Adjuvant chemotherapy is associated with improved overall survival in pelvic node-positive penile cancer after lymph node dissection: a multi-institutional study. Urol Oncol 2015; 33 (11) 496.e17-496.e23
- 10 Patil VM, Noronha V, Joshi A. et al. Palliative chemotherapy in carcinoma penis: does platinum and taxane combination holds a promise?. Urol Ann 2014; 6 (01) 18-22
- 11 Mailankody S, Radhakrishnan V, Raja A, Ganesan TS, Dhanushkodi M, Sagar TG. Outcomes with chemotherapy in carcinoma penis: experience from a tertiary cancer center. Indian J Cancer 2023; 60 (03) 396-402
- 12 Shah AA, Shah HA, Panjwani GN, Pandey BB, Shah N. Prognostic factors and 5-year survival of patients with carcinoma penis: tertiary health center study. Indian J Cancer 2016; 53 (02) 309-312
- 13 Noronha V, Kapu V, Joshi A. et al. Clinical profile and outcomes of carcinoma penis patients receiving systemic therapy at an Indian tertiary care center: a retrospective observational study. Clin Genitourin Cancer 2024; 22 (03) 102053
- 14 Maden C, Sherman KJ, Beckmann AM. et al. History of circumcision, medical conditions, and sexual activity and risk of penile cancer. J Natl Cancer Inst 1993; 85 (01) 19-24
- 15 Vieira CB, Feitoza L, Pinho J. et al. Profile of patients with penile cancer in the region with the highest worldwide incidence. Sci Rep 2020; 10 (01) 2965
- 16 Sirithanaphol W, Sookprasert A, Rompsaithong U, Kiatsopit P, Wirasorn K, Chindaprasirt J. Prognostic factors for penile cancer and survival in response to multimodality therapy. Res Rep Urol 2020; 12: 29-34